New Research Finds Changing Surgical Gloves and Instruments Significantly Reduces Surgical Site Infections

A new study published in The Lancet, one of the world’s most prestigious medical journals, has clearly demonstrated the value of routinely changing gloves and instruments prior to abdominal wound closure, offering one of the first proven methods of reducing surgical site infection (SSI), the most common complication of surgery worldwide.

The paper, “Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomized trial in seven low-income and middle-income countries,” was published October 31, 2022.

“The ChEETAh trial found that routine change of gloves and instruments before abdominal wound closure reduced the rate of surgical site infection (SSI) by 13% at 30 days after surgery compared with the trial control group, which is equivalent to a reduction of one in every eight SSIs,” the paper states.

A total of 13,301 patients were recruited into the ChEETAh trial, which took place between June 2020 and March 2022.

This reduction in SSI was seen across the trial, from large hospitals with advanced perioperative services to small, rural hospitals with only a few beds. The paper concludes that, “this trial showed a robust benefit to routinely changing gloves and instruments before abdominal wound closure.  We suggest that it should be widely implemented into surgical practice around the world.”

Mölnlycke, a world-leading medical solutions company, donated sterile Biogel® surgical gloves to participating sites, helping to support this important initiative.

“The cost of SSIs, both in terms of human suffering and healthcare costs is staggering,” said Emma Wright, Chief Medical Officer, Mölnlycke. “The simple, cost-effective process of changing gloves and instruments prior to surgical closure is a best practice that will improve lives around the world. At Mölnlycke, we are deeply committed to supporting the development of evidence-based best practices and improving outcomes utilizing high-quality medical devices.”

As noted in the paper, SSI continues to be the most common complication of surgery worldwide, disproportionately affecting patients in both low and middle-income countries. Unfortunately, the causes of SSI are many and very few interventions to reduce their occurrence have been proven effective.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”